Candriam Luxembourg S.C.A. decreased its position in shares of Humana Inc. (NYSE:HUM) by 72.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,190 shares of the insurance provider’s stock after selling 13,518 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Humana were worth $934,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Retirement Systems of Alabama raised its position in shares of Humana by 0.7% in the second quarter. Retirement Systems of Alabama now owns 75,981 shares of the insurance provider’s stock worth $13,667,000 after buying an additional 531 shares during the last quarter. WESPAC Advisors LLC raised its position in shares of Humana by 9.6% in the second quarter. WESPAC Advisors LLC now owns 7,013 shares of the insurance provider’s stock worth $1,261,000 after buying an additional 615 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Humana during the second quarter worth approximately $14,049,000. Shell Asset Management Co. raised its position in shares of Humana by 47.1% in the second quarter. Shell Asset Management Co. now owns 31,778 shares of the insurance provider’s stock worth $5,716,000 after buying an additional 10,176 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Humana by 29.4% in the second quarter. Daiwa Securities Group Inc. now owns 4,400 shares of the insurance provider’s stock worth $791,000 after buying an additional 1,000 shares during the last quarter. 93.24% of the stock is owned by institutional investors.
Shares of Humana Inc. (NYSE:HUM) traded up 0.29% during mid-day trading on Friday, reaching $177.74. The company’s stock had a trading volume of 861,509 shares. The stock has a 50 day moving average of $176.80 and a 200-day moving average of $176.07. The stock has a market cap of $26.50 billion, a P/E ratio of 27.31 and a beta of 0.90. Humana Inc. has a one year low of $150.00 and a one year high of $191.65.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.23 by $0.07. The company earned $14 billion during the quarter, compared to analyst estimates of $13.59 billion. Humana had a return on equity of 11.11% and a net margin of 1.76%. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.67 earnings per share. On average, equities research analysts expect that Humana Inc. will post $9.24 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Thursday, October 13th will be given a $0.29 dividend. The ex-dividend date of this dividend is Tuesday, October 11th. This represents a $1.16 annualized dividend and a yield of 0.65%. Humana’s payout ratio is 18.18%.
A number of equities research analysts have issued reports on the company. Cantor Fitzgerald restated a “buy” rating on shares of Humana in a research report on Saturday, July 9th. RBC Capital Markets restated a “buy” rating and set a $224.00 price objective (up from $220.00) on shares of Humana in a research report on Friday, July 22nd. Credit Suisse Group AG restated a “hold” rating and set a $188.00 price objective on shares of Humana in a research report on Tuesday, September 13th. Jefferies Group restated a “buy” rating and set a $220.00 price objective (up from $210.00) on shares of Humana in a research report on Monday, July 25th. Finally, Barclays PLC decreased their price objective on Humana from $193.00 to $191.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Humana currently has a consensus rating of “Buy” and a consensus price target of $201.00.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.